Cargando…
Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives
Neisseria meningitidis causes severe invasive meningococcal diseases (IMDs) in humans including meningitis and septicemia, responsible for serious clinical conditions and leading to life-long disabilities and death. Serogroup B dominates IMDs burden in Italy, accounting for over 60% of total cases....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore SPA
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755121/ https://www.ncbi.nlm.nih.gov/pubmed/26788733 |
_version_ | 1782416147696582656 |
---|---|
author | SIGNORELLI, C. CHIESA, V. ODONE, A. |
author_facet | SIGNORELLI, C. CHIESA, V. ODONE, A. |
author_sort | SIGNORELLI, C. |
collection | PubMed |
description | Neisseria meningitidis causes severe invasive meningococcal diseases (IMDs) in humans including meningitis and septicemia, responsible for serious clinical conditions and leading to life-long disabilities and death. Serogroup B dominates IMDs burden in Italy, accounting for over 60% of total cases. On January 2013 the European Medicine Agency (EMA) licensed the first serogroup B meningococcal (MenB) vaccine in Europe. A number of European countries and Regions have introduced the new MenB vaccine in their immunization schedule, including Italy. In this paper we present the state of art, related critical issues and future perspectives of MenB vaccine introduction in Italy, in the context of the most recent available epidemiological data. In particular, we systematically assess the ongoing processes in the 8 Italian regions and one autonomous province that have already introduced MenB vaccine. With the new 2014-2018 National Vaccine Prevention Plan including active MenB vaccine offer about to be adopted, it is of fundamental importance to gather further evidence on MenB vaccine clinical effectiveness, duration of protection and cost-effectiveness. Italian regions are called to organize and manage MenB immunization programs. Careful consideration will need to be devoted on timing, doses, and co-administration with other vaccines but also to economic assessments and strengthened communication to the general public. Our data will help to plan, implement and evaluate MenB immunization programmes in other Italian and international settings. |
format | Online Article Text |
id | pubmed-4755121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Pacini Editore SPA |
record_format | MEDLINE/PubMed |
spelling | pubmed-47551212016-02-19 Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives SIGNORELLI, C. CHIESA, V. ODONE, A. J Prev Med Hyg Review Neisseria meningitidis causes severe invasive meningococcal diseases (IMDs) in humans including meningitis and septicemia, responsible for serious clinical conditions and leading to life-long disabilities and death. Serogroup B dominates IMDs burden in Italy, accounting for over 60% of total cases. On January 2013 the European Medicine Agency (EMA) licensed the first serogroup B meningococcal (MenB) vaccine in Europe. A number of European countries and Regions have introduced the new MenB vaccine in their immunization schedule, including Italy. In this paper we present the state of art, related critical issues and future perspectives of MenB vaccine introduction in Italy, in the context of the most recent available epidemiological data. In particular, we systematically assess the ongoing processes in the 8 Italian regions and one autonomous province that have already introduced MenB vaccine. With the new 2014-2018 National Vaccine Prevention Plan including active MenB vaccine offer about to be adopted, it is of fundamental importance to gather further evidence on MenB vaccine clinical effectiveness, duration of protection and cost-effectiveness. Italian regions are called to organize and manage MenB immunization programs. Careful consideration will need to be devoted on timing, doses, and co-administration with other vaccines but also to economic assessments and strengthened communication to the general public. Our data will help to plan, implement and evaluate MenB immunization programmes in other Italian and international settings. Pacini Editore SPA 2015-08 /pmc/articles/PMC4755121/ /pubmed/26788733 Text en © Copyright by Pacini Editore SPA, Pisa, Italy http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License, which permits for noncommercial use, distribution, and reproduction in any digital medium, provided the original work is properly cited and is not altered in any way. For details, please refer to http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Review SIGNORELLI, C. CHIESA, V. ODONE, A. Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives |
title | Meningococcal serogroup B vaccine in Italy:
state-of-art, organizational aspects and perspectives |
title_full | Meningococcal serogroup B vaccine in Italy:
state-of-art, organizational aspects and perspectives |
title_fullStr | Meningococcal serogroup B vaccine in Italy:
state-of-art, organizational aspects and perspectives |
title_full_unstemmed | Meningococcal serogroup B vaccine in Italy:
state-of-art, organizational aspects and perspectives |
title_short | Meningococcal serogroup B vaccine in Italy:
state-of-art, organizational aspects and perspectives |
title_sort | meningococcal serogroup b vaccine in italy:
state-of-art, organizational aspects and perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755121/ https://www.ncbi.nlm.nih.gov/pubmed/26788733 |
work_keys_str_mv | AT signorellic meningococcalserogroupbvaccineinitalystateofartorganizationalaspectsandperspectives AT chiesav meningococcalserogroupbvaccineinitalystateofartorganizationalaspectsandperspectives AT odonea meningococcalserogroupbvaccineinitalystateofartorganizationalaspectsandperspectives |